Acelrx Pharmaceuticals Inc (NASDAQ:ACRX) Sellers Reduced By 1.55% Their Shorts As Of Apr 17, 2018

April 17, 2018 - By Eula Gilbert

AcelRx Pharmaceuticals, Inc. (NASDAQ:ACRX) Corporate Logo

Big Money Sentiment increased to 0.83 in 2017 Q4. It has change of 0.13, from 2017Q3’s 0.7. The ratio improved due to AcelRx Pharmaceuticals, Inc. positioning: 8 sold and 15 reduced. 7 funds took holdings and 12 increased holdings. Investors holded 6.65 million in 2017Q3 but now own 4.57 million shares or 31.27% less.
Da Davidson And Co accumulated 0% or 63,500 shs. Bridgeway Cap Mgmt invested 0.01% of its capital in AcelRx Pharmaceuticals, Inc. (NASDAQ:ACRX). Bnp Paribas Arbitrage Sa owns 8 shs for 0% of their capital. D E Shaw & Incorporated reported 0% of its capital in AcelRx Pharmaceuticals, Inc. (NASDAQ:ACRX). 647,467 are owned by Blackrock. Moreover, Goldman Sachs Gp has 0% invested in AcelRx Pharmaceuticals, Inc. (NASDAQ:ACRX). One Trading Lp has invested 0% of its capital in AcelRx Pharmaceuticals, Inc. (NASDAQ:ACRX). Morgan Stanley holds 0% or 17,537 shs in its capital. Wells Fargo Co Mn reported 0% in AcelRx Pharmaceuticals, Inc. (NASDAQ:ACRX). Guggenheim Capital Ltd has 10,665 shs. Joel Isaacson & Co Ltd Liability Com, New York-based fund reported 70,000 shs. Natixis stated it has 0% of its capital in AcelRx Pharmaceuticals, Inc. (NASDAQ:ACRX). Cornerstone Cap Inc has invested 0.01% of its capital in AcelRx Pharmaceuticals, Inc. (NASDAQ:ACRX). Bank & Trust Of New York Mellon owns 54,329 shs. Deutsche Retail Bank Ag reported 89 shs or 0% of all its holdings.

It was recorded a decrease on Acelrx Pharmaceuticals Inc (NASDAQ:ACRX)’s shorted shares with 1.55%. FINRA announced in April ACRX’s total 4.62M shorted shares. The down change of 1.55% from 4.69 million shares was reported. Former ACRX’s position will need 10 days to restore. It has 470,400 average volume. 12.5% is Acelrx Pharmaceuticals Inc float short.

The stock increased 6.67% or $0.15 during the last trading session, reaching $2.4.AcelRx Pharmaceuticals, Inc. is downtrending after having declined 27.87% since April 17, 2017. ACRX has 1.00 million volume or 110.42% up from normal. ACRX underperformed the S&P 500 by 39.42%.

AcelRx Pharmaceuticals, Inc., a specialty pharmaceutical company, focuses on the development and commercialization of therapies for the treatment of acute pain.The firm is valued at $122.16 million. The Company’s lead product candidate is DSUVIA, a 30 mcg sufentanil sublingual tablet, which is in Phase III clinical trial for the treatment of moderate-to-severe acute pain.Last it reported negative earnings. The companyÂ’s late-stage investigational product candidate is Zalviso, a pre-programmed and patient-controlled analgesia device that allows hospital patients with moderate-to-severe acute pain to self-dose with sufentanil sublingual tablets to manage their pain.

AcelRx Pharmaceuticals, Inc. (NASDAQ:ACRX) Analyst Ratings Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.





Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: